Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/19420862.2020.1804241 http://scihub22266oqcxt.onion/10.1080/19420862.2020.1804241 32804015!7531490!32804015     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       MAbs 2020 ; 12 (1): 1804241 Nephropedia Template TP {{tp|p=32804015|t=2020. A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy |pdf=|usr=}}{{32804015}} gab.com Text A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy JO: MAbs http://www.kidney.de/pget.php?&tw=1&pmid=32804015 #FOAvip In the absence of a proven effective vaccine preventing infection by SARS-CoV-2, or a proven drug to treat COVID-19, the positive results of passive immune therapy using convalescent serum provide a strong lead. We have developed a new class of tetravalent, biparatopic therapy, 89C8-ACE2. It combines the specificity of a monoclonal antibody (89C8) that recognizes the relatively conserved N-terminal domain of the viral Spike (S) glycoprotein, and the ectodomain of ACE2, which binds to the receptor-binding domain of S. This molecule shows exceptional performance in vitro, inhibiting the interaction of recombinant S1 to ACE2 and transduction of ACE2-overexpressing cells by S-pseudotyped lentivirus with IC50s substantially below 100 pM, and with potency approximately 100-fold greater than ACE2-Fc itself. Moreover, 89C8-ACE2 was able to neutralize authentic viral infection in a standard 96-h co-incubation assay at low nanomolar concentrations, making this class of molecule a promising lead for therapeutic applications. Twit Text FOAVip A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy ????MAbs http://www.kidney.de/pget.php?&tw=1&pmid=32804015 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32804015 #FOAvip English Wikipedia <ref>{{Cite pmid|32804015}}</ref> A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy #MMPMID32804015 Miao X; Luo Y; Huang X; Lee SMY; Yuan Z; Tang Y; Chen L; Wang C; Wu F; Xu Y; Jiang W; Gao W; Song X; Yan Y; Pang T; Chen C; Zou Y; Fu W; Wan L; Gilbert-Jaramillo J; Knight M; Tan TK; Rijal P; Townsend A; Sun J; Liu X; James W; Tsun A; Xu Y MAbs 2020[Jan]; 12 (1): 1804241 PMID32804015show ga In the absence of a proven effective vaccine preventing infection by SARS-CoV-2, or a proven drug to treat COVID-19, the positive results of passive immune therapy using convalescent serum provide a strong lead. We have developed a new class of tetravalent, biparatopic therapy, 89C8-ACE2. It combines the specificity of a monoclonal antibody (89C8) that recognizes the relatively conserved N-terminal domain of the viral Spike (S) glycoprotein, and the ectodomain of ACE2, which binds to the receptor-binding domain of S. This molecule shows exceptional performance in vitro, inhibiting the interaction of recombinant S1 to ACE2 and transduction of ACE2-overexpressing cells by S-pseudotyped lentivirus with IC50s substantially below 100 pM, and with potency approximately 100-fold greater than ACE2-Fc itself. Moreover, 89C8-ACE2 was able to neutralize authentic viral infection in a standard 96-h co-incubation assay at low nanomolar concentrations, making this class of molecule a promising lead for therapeutic applications. |*Coronavirus Infections[MESH] |*Pandemics[MESH] |*Pneumonia, Viral[MESH] |Angiotensin-Converting Enzyme 2[MESH] |Antibodies, Monoclonal/pharmacology[MESH] |Antibodies, Neutralizing/*pharmacology[MESH] |Antibodies, Viral/*pharmacology[MESH] |Betacoronavirus/*drug effects[MESH] |COVID-19[MESH] |Drug Design[MESH] |Drug Discovery[MESH] |Humans[MESH] |Peptidyl-Dipeptidase A/*drug effects[MESH] |Recombinant Proteins[MESH] |SARS-CoV-2[MESH]A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2(epmc).pdf DeepDyve Pubget Overpricing